Zacks Research Upgrades USANA Health Sciences (NYSE:USNA) to “Hold”

USANA Health Sciences (NYSE:USNA) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday, Zacks reports.

A number of other brokerages also recently commented on USNA. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Wall Street Zen cut shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce”.

USANA Health Sciences Price Performance

NYSE:USNA opened at $14.91 on Monday. USANA Health Sciences has a 1-year low of $12.57 and a 1-year high of $26.76. The firm’s fifty day moving average price is $15.15 and its 200 day moving average price is $17.85. The firm has a market cap of $275.61 million, a price-to-earnings ratio of -12.33, a price-to-earnings-growth ratio of 1.63 and a beta of 0.68.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.50). USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.The firm had revenue of $223.27 million for the quarter, compared to analysts’ expectations of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. As a group, analysts expect that USANA Health Sciences will post 0.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc increased its holdings in USANA Health Sciences by 1,472.3% during the 2nd quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock worth $34,000 after purchasing an additional 1,487 shares during the last quarter. State of Wyoming purchased a new position in shares of USANA Health Sciences during the 1st quarter valued at approximately $57,000. GSA Capital Partners LLP bought a new stake in shares of USANA Health Sciences in the second quarter worth $250,000. DGS Capital Management LLC acquired a new stake in USANA Health Sciences in the first quarter valued at $208,000. Finally, Ieq Capital LLC acquired a new stake in USANA Health Sciences in the second quarter valued at $300,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops and sells nutritional supplements, personal-care products and foods designed to support general health and wellness. Its product portfolio includes vitamins and mineral supplements, herbal and specialty nutritional products, meal-replacement and snack items, and skincare products marketed under the USANA and Sensé brands.

Founded in 1992 by immunologist Myron Wentz, USANA distributes its products primarily through a direct-selling model involving independent associates.